These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 15262499

  • 1. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
    Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menéndez-Arias L, Martínez MA, Martinez-Picado J.
    Virology; 2004 Aug 15; 326(1):103-12. PubMed ID: 15262499
    [Abstract] [Full Text] [Related]

  • 2. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE, Franco S, Martínez MA, Menéndez-Arias L.
    J Mol Biol; 2007 Jan 12; 365(2):298-309. PubMed ID: 17070543
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W.
    J Virol; 2004 Jul 12; 78(14):7545-52. PubMed ID: 15220429
    [Abstract] [Full Text] [Related]

  • 7. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
    Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M.
    J Infect Dis; 2002 Apr 01; 185(7):898-904. PubMed ID: 11920313
    [Abstract] [Full Text] [Related]

  • 8. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W, Matsuda M, Matsuda Z, Abumi H, Okano A, Oishi T, Moriya K, Yamamoto Y, Fukutake K, Mimaya J, Ajisawa A, Taki M, Yamada K, Nagai Y.
    J Hum Virol; 1999 Apr 01; 2(3):146-53. PubMed ID: 10413366
    [Abstract] [Full Text] [Related]

  • 9. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M, Mendieta J, Puertas MC, Parera M, Martínez MA, Martinez-Picado J, Menéndez-Arias L.
    J Mol Biol; 2008 Oct 03; 382(2):327-41. PubMed ID: 18662701
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
    Sato H, Tomita Y, Ebisawa K, Hachiya A, Shibamura K, Shiino T, Yang R, Tatsumi M, Gushi K, Umeyama H, Oka S, Takebe Y, Nagai Y.
    J Virol; 2001 Jun 03; 75(12):5604-13. PubMed ID: 11356968
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
    Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM.
    Virology; 2001 Jul 05; 285(2):193-203. PubMed ID: 11437654
    [Abstract] [Full Text] [Related]

  • 16. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA, Demeter LM.
    Int J Biochem Cell Biol; 2004 Sep 05; 36(9):1735-51. PubMed ID: 15183341
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.
    Antimicrob Agents Chemother; 2006 Aug 18; 50(8):2772-81. PubMed ID: 16870771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.